PBSCT without the Use of Growth Factors Post Transplant: Cost Savings without Clinical Consequences. Is It Time for a Change in Standard Practice? by Schriber, Jeffrey, MD, Simpson, Eileen, BS, MT, Fauble, Veena, MD, Go, Aileen, MD, Szetela, Andrew, PharmD, BCOP, Kendrick, Selma, RN MS, Abbas, Jonathan, M.D, Briggs, Adrienne, MD

Get full text

Post Transplant Cytoxan in Patients over the Age of 60 Undergoing Allogeneic Transplant: Less Graft Versus Host Disease (GVHD) Related Deaths Than in Patients Treated with Standard... by Schriber, Jeffrey, MD, Fauble, Veena, MD, Simpson, Eileen, BS, MT, Steenstra, Kate, MS, FNP, Chiffelle, Rochelle, DNP, Sulski, Gail, MS, FNP, Thurman, Nicole, MS, FNP, Go, Aileen, MD, Kendrick, Selma, RN MS, Abbas, Jonathan, M.D, Briggs, Adrienne, MD

Get full text

Single Dose Plerixafor and Multi-Day Apheresis: Skip Dosing Enables Cost Efficient Mobilization for Patients Close to Achieving Treatment Goals by Schriber, Jeffrey, MD, Szetela, Andrew, PharmD, BCOP, Schriber, Aleksandra, Simpson, Eileen, BS, MT, Israel, Donald, BSc, Sulski, Gail, MS, FNP, Thurman, Nicole, MS, FNP, Chiffelle, Rochelle, DNP, Steenstra, Kate, MS, FNP, Gibson, Denise, RN, MSN, Kendrick, Selma, RN MS, Abbas, Jonathan, M.D, Briggs, Adrienne, MD

Get full text